Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 19 S1 2020 05 17 13 17 Seyed-Mohammad Ghahestani Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran Javad Mahmoudi Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Sakineh Hajebrahimi Research Center for Evidence-Based-Medicine, Iranian EBM Center, A JBI Affiliated Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran AND Department of Urology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran Amir-Babak Sioofy-Khojine Research Center for Evidence-Based-Medicine, Iranian EBM Center, A JBI Affiliated Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran AND Faculty of Medicine and Life Technologies, Tampere University, Tampere, Finland AND Research Center for Infectious and Tropical Disease, Tabriz University of Medical Sciences, Tabriz, Iran Hanieh Salehi-Pourmehr Research Center for Evidence-Based-Medicine, Iranian EBM Center, A JBI Affiliated Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran Fatemeh Sadeghi-Ghyassi Research Center for Evidence-Based-Medicine, Iranian EBM Center, A JBI Affiliated Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iranersity of Medical Sciences, Tabriz, Iran 7 Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Hadi Mostafaei Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria 2020 04 11 2020 04 22 The new virus SARS-CoV-2 is savagely spreading out over the world. The biologic studies show that the target receptor for the virus might be angiotensin-converting enzyme 2 (ACE2). This peptide is responsible for converting angiotensin II (Ang II), which is a profoundly active peptide, into Ang 1-7 with quite a balancing barbell function. It is emphasized that the direct target of the virus is ACE2 underlining the obvious difference with ACE. Nevertheless, we hypothesized that a back load build up effect on Ang II may usurp the ACE capacity and subsequently leave the bradykinin system unabated. We think there are clinical clues for dry cough and the presumed aggravating role of ACE inhibitors like captopril on the disease process. Thereby, we speculated that inhibition of bradykinin synthesis and/or blockade of bradykinin B2 receptor using Aprotinin/ecallantide and Icatibant, respectively, may hold therapeutic promise in severe cases and these molecules can be advanced to clinical trials. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2785